- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05697068
Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos
January 24, 2025 updated by: Noe Crespo, San Diego State University
Tailored Behavioral Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos
This study will examine the effectiveness of a 6-week behavioral intervention for patients who are recently diagnosed with COVID-19.
Patients and their households will be randomized to one of two groups (Standard of Care vs.
Enhanced Standard of Care).
Patients in the Standard-of-Care group will receive established clinical care and follow-up.
Patients in the Enhanced Standard-of-Care group will receive standard-of-care plus tailored, real-time text messaging and virtual counseling delivered by promotores/as.
The investigators hypothesize that households in the Enhanced Standard-of-Care group will have fewer (any new) household COVID-19 infectivity rates compared to households in the standard-of-care group post-intervention.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study team will develop and test a novel tailored behavioral intervention for patients of a Federally Qualified Health Center who are recently diagnosed with COVID-19.
The study is a pragmatic, quality improvement randomized controlled trial (RCT).
This research is looking to enroll 256 index patients and their households.
Index patients and their households will be invited to participate in the COVID Prevention Program, which includes free COVID-19 testing for exposed household members.
Index patients will be randomized to one of two groups: (a) the Standard-of-Care comparison group who will receive established clinical care and follow-up, or (b) the Enhanced Standard-of-Care group, who will receive standard-of-care plus tailored, real-time mobile/virtual counseling delivered by promotores/as.
The intervention will use theory- and evidence-based strategies for behavior change and maximize the use of mobile phone applications and technologies to capture real-time behavioral, social, and contextual data (via Ecological Momentary Assessment).
The intervention will utilize motivational interviewing techniques to tailor strategies to index patients' home environment/context and social/emotional needs.
The intervention will target immediate risk of household spread, followed by risk of community spread.
The primary outcome assessed will be a new positive antibody test within a household (post-baseline), as assessed by a blood draw collected by a certified phlebotomist.
Secondary research outcomes will be assessed via self-report surveys.
Surveys will include socioeconomic status indicators and demographics, as well as measures of mental health (e.g., depression), physical health (chronic conditions), health behaviors (social distancing, hand washing & wearing face covering), as well as comorbidities and risk factors for severe COVID-19 outcomes.
Primary and secondary outcomes will be measured at 5 timepoints: baseline, 6-weeks, 6-months, 12-months, and 24-months.
Study Type
Interventional
Enrollment (Actual)
256
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92182
- San Diego State University Research Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adult patients of a federally qualified health center (+18yrs)
- Test positive for COVID-19
Exclusion Criteria:
- Planning to move out of state in the next year
- Cognitive impairment that is contraindicated to receiving counseling and following behavioral strategies (e.g., schizophrenia, Down syndrome)
- Living in a transitionary home or homeless.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard-of-Care
Patients who test positive will receive a call from the provider who conducted the test to notify them of the test result and provide standard-of-care counseling (e.g., health education, link them to resources).
Index patients are entered into a COVID-19 patient registry in the Federally Qualified Health Center's electronic health record system (which also is linked to the clinic's COVID-19 dashboard) and monitored closely, with telemedicine follow-ups provided by skilled clinical staff every two-to-three days, and in-person follow-ups provided as needed.
|
This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2.
The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread.
Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling).
Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic.
Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months.
Written informed consent will be obtained for all research activities occurring outside of clinical care.
|
|
Experimental: Enhanced Standard-of-Care
In addition to the aforementioned standard-of-care actions, index patients in the enhanced standard-of-care group will receive tailored phone/mobile counseling (motivational interviewing) focused on implementing strategies to prevent immediate household spread of COVID-19, followed by weekly text messaging for a total of 6 weeks.
|
This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2.
The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread.
Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling).
Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic.
Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months.
Written informed consent will be obtained for all research activities occurring outside of clinical care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of households with SARS-CoV-2 Antibodies
Time Frame: Baseline & 1-, 6-, 12-, and 24-months post-baseline.
|
Antibodies assessed by a blood draw collected by a certified phlebotomist.
SARS-CoV-2 Nucleocapsid and Spike Protein IgG, used to accurately determine prior infection and/or vaccination.
|
Baseline & 1-, 6-, 12-, and 24-months post-baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of households with SARS-CoV-2 Active Infection
Time Frame: Baseline, 3-5 days post-baseline, and 7-9 days post-baseline.
|
Active infection assessed by self-administered anterior nasal swab.
SARS-CoV-2 RT-PCR used to determine if exposed household member has been infected and/or can exit quarantine early.
|
Baseline, 3-5 days post-baseline, and 7-9 days post-baseline.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with risk reduction behaviors
Time Frame: Baseline & 1-, 6-, 12-, and 24-months post-baseline.
|
Secondary outcomes measured via self-report surveys.
Surveys include socioeconomic status indicators and demographics, measures of mental health (e.g., depression), physical health (chronic conditions) and health behaviors (social distancing, hand washing & wearing face covering), comorbidities, and risk factors for severe COVID-19 outcomes.
|
Baseline & 1-, 6-, 12-, and 24-months post-baseline.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Noe C Crespo, M.P.H, Ph.D., San Diego State University Research Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 11, 2022
Primary Completion (Actual)
September 9, 2024
Study Completion (Estimated)
October 31, 2025
Study Registration Dates
First Submitted
January 20, 2023
First Submitted That Met QC Criteria
January 20, 2023
First Posted (Actual)
January 25, 2023
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 24, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MD016324 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2 Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Kamuzu University... and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionCompleted
-
Indiana UniversityCompletedSARS-CoV-2United States
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District... and other collaboratorsCompleted
-
University Hospital, Montpelliersociete SkillCell - 97198 Jarry; CNRS Alcediag UMR9005 - societe Sys2Diag -...Completed
-
Centre Hospitalier Universitaire DijonCompleted
Clinical Trials on COVID Prevention Program (CPP)
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
McMaster UniversityActive, not recruitingDiabetes Mellitus | Multiple Chronic ConditionsCanada
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedConsultation (LLS) | Consultation and Coaching (HLS)United States
-
The University of Texas Medical Branch, GalvestonWithdrawnHypertension | Prediabetic State | Overweight or Obesity | Gestational Weight Gain
-
Assistance Publique - Hôpitaux de ParisCompletedSuicide, AttemptedFrance
-
Montana State UniversityCompletedDiabetes Mellitus, Type 2United States
-
Baylor Research InstituteUniversity of North Texas Health Science CenterCompletedObesity | Pre-diabetesUnited States
-
University of TorontoCompletedCovid19Canada, India, Thailand
-
Blue Marble Rehab IncNational Institute on Aging (NIA); Partners In Care FoundationCompleted
-
Samara State Medical UniversityActive, not recruitingCarious and Non-carious Lesions of the TeethRussian Federation